Related Experiment Video
Updated: Nov 18, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
Published on: January 17, 2025
Implementing Person-Centered, Clinical, and Research Navigation in Rare Cancers: The Canadian Cholangiocarcinoma
Samar Attieh1,2, Leonard Angka2, Christine Lafontaine2
1Department of Surgery, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Person-centered navigation (PCN) supports rare cancer patients by connecting them to timely screening, treatment, and psychosocial support. The Canadian Cholangiocarcinoma Collaborative (C3) uses a virtual PCN model for Biliary Tract Cancers (BTCs).
Area of Science:
- Oncology
- Healthcare Navigation
- Patient Support Systems
Background:
- Person-centered navigation (PCN) is a collaborative approach to guide patients through healthcare.
- PCN is vital for rare cancers due to challenges like uncertainty, limited support, and access difficulties.
- Biliary Tract Cancers (BTCs) represent a group of rare cancers requiring specialized navigation.
Purpose of the Study:
- To implement and evaluate a virtual Person-centered Navigation (PCN) model for Biliary Tract Cancers (BTCs).
- To address the unique challenges faced by rare cancer patients, including access to information, testing, and psychosocial support.
- To facilitate patient access to clinical trials, molecular testing, and expert consultations.
Main Methods:
- The Canadian Cholangiocarcinoma Collaborative (C3) employs a virtual PCN model.
- A dedicated "C3 Research Navigator" provides personalized guidance, support, and facilitates access to services.
- Implementation strategies include co-design, timely support delivery, and leveraging a national network of BTC experts.
Main Results:
- The C3 virtual PCN model facilitates access to molecular testing, clinical trials, and multidisciplinary case reviews.
- Established a national network of BTC experts and a patient research registry.
- Initiated advocacy activities to support the BTC patient community.
Conclusions:
- The virtual PCN model implemented by C3 effectively addresses challenges in rare cancer care, specifically for BTCs.
- Future priorities include network expansion, enhanced user engagement, and integration into routine clinical practice.
- PCN is a critical component for improving outcomes and patient experience in rare cancer management.
More Related Videos
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...

